Hamad Medical Corporation (HMC) has launched the Kidney Transplant Precision Medicine Program, a collaborative initiative between the medical genetics and kidney transplant departments. This program marks a significant advancement in kidney transplant care, focusing on high-risk patients with hereditary kidney diseases.
Dr. Hassan Al Malki, Head of the Nephrology Division and Director of the Nephrology Transplant Program at HMC, emphasized that the program leverages advanced genetic testing to tailor treatments based on each patient’s unique genetic profile. “By applying personalized and genomic medicine, we can improve transplant safety and outcomes, enhancing the quality of life for patients and their donors,” Dr. Al Malki explained.
Reem Ibrahim Bux, Clinical Lead of Adult and Reproductive Genetic Counseling Services, noted that the program identifies genetic conditions such as polycystic kidney disease and Alport syndrome that could impact both donors and recipients. “Our goal is to interpret genetic test results, helping families understand potential risks and make informed treatment decisions,” she said.
Dr. Reem Al Sulaiman, Acting Chair of HMC’s Medical Genetics Department, highlighted that the program exemplifies precision medicine by integrating genomics into transplant care. “This initiative bridges research with clinical practice, allowing for more personalized and cost-effective transplant plans,” she stated, adding that it aligns with HMC’s vision to advance healthcare in Qatar.
Dr. Yousef Al Maslamani, Director of the Qatar Center for Organ Transplantation, remarked that the program improves safety for both patients and donors. “It also sets the stage for expanding precision medicine strategies to other organ transplants in the future,” he added.